|
Post by JHam on Jul 18, 2014 19:47:14 GMT
Bioheart, Inc. is a development-stage, biotechnology company. The Company focuses on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company’s clinical trials of MyoCell include the SEISMIC Trial, which completed a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe; the MYOHEART Trial, a completed 20-patient, multicenter, Phase I dose-escalation trial conducted in the United States, and the MARVEL Trial, a 330-patient, multicenter Phase II/III trial of MyoCell in North America and Europe.
|
|
|
Post by JHam on Jul 18, 2014 19:53:51 GMT
I would strongly suggest reading through this thread from the Google Board before deciding to open a position in this company: groups.google.com/d/msg/the-act-discussion-forum/aypxF47y6V8/HiWpX0GYunUJAt one time I thought this was a potential good trade due to upcoming Regen trial results, a trial which I later found out had been put on hold. That is when I sold and started to really learn more about this company. This is a long thread, but it is definitely worth the read. Especially from around the middle onward.
|
|
|
Post by dayanand33 on Jul 18, 2014 19:54:36 GMT
Has been a steady rise with no news and minuscule volume. I saw Feed pumping this stock on icell. But that was last month.
|
|
hphan
New Member
Posts: 7
|
Post by hphan on Jul 18, 2014 20:08:53 GMT
i bought into BHRT last fall and did sell off half my holdings a couple months ago for a nice 500% gain. i don't expect them to really ever go legit, but it has been lucrative for me so far. i'll probably dump the rest if it crests $.05 again.
|
|
|
Post by dayanand33 on Jul 19, 2014 11:22:12 GMT
I would strongly suggest reading through this thread from the Google Board before deciding to open a position in this company: groups.google.com/d/msg/the-act-discussion-forum/aypxF47y6V8/HiWpX0GYunUJAt one time I thought this was a potential good trade due to upcoming Regen trial results, a trial which I later found out had been put on hold. That is when I sold and started to really learn more about this company. This is a long thread, but it is definitely worth the read. Especially from around the middle onward. I am unable to view anything after 1st page. None of the other pages get rendered. I have been trying for the past 2 days. Is anyone else observing the same? groups.google.com/d/msg/the-act-discussion-forum/aypxF47y6V8/HiWpX0GYunUJ
|
|
|
Post by JHam on Jul 19, 2014 15:11:44 GMT
You're right. Strange. Let me work on that. Thanks for letting me know.
|
|
|
Post by JHam on Jul 20, 2014 17:45:29 GMT
It looks like some of the very old and long threads are not opening from the Google board. That's disappointing. Lucky we still have the email thread saved with all of the posts intact. When I get back home in the next few days I'll copy and paste some of the more important posts in that thread.
|
|
|
Post by JHam on Jul 21, 2014 6:20:10 GMT
The Google Board thread is now viewable. At least it started working for me again. I'll probably still go ahead and start a separate thread here with important nuggets of information from that thread, to save people time from having to go through the whole thing.
Anyone considering investing in this company really must read through that thread before going through with anything.
|
|
|
Post by dayanand33 on Jul 21, 2014 18:24:53 GMT
The Google Board thread is now viewable. At least it started working for me again. I'll probably still go ahead and start a separate thread here with important nuggets of information from that thread, to save people time from having to go through the whole thing. Anyone considering investing in this company really must read through that thread before going through with anything. Thanks Jham. Did you have to do anything to get it working or the problem just went away?
|
|
|
Post by JHam on Jul 22, 2014 2:32:31 GMT
I tried to open a thread in one of the middle pages via email. It took a while for it to load after clicking the link, but eventually there it was. I'm not sure if that had anything to do with it or if it just decided to finally open. I'd like to think it had something to do with my guru-like computer skills...<awkward silence>
|
|
|
Post by JHam on Jul 24, 2014 15:21:39 GMT
|
|
|
Post by wayanadan on Jul 24, 2014 22:17:35 GMT
How do you assume this is life threatening?
|
|
|
Post by dayanand33 on Jul 24, 2014 23:07:49 GMT
May not be life threatening but may not be life saving either. I went through the google thread on this stock. It did convince me that this is a sham company. But I hate to say that I still put some money into this stock yesterday. Why? Because I believe this stock is a pump and dump stock. Sooner or later some folks are going to pump this crap. Stocks like bhrt and cbai will be good picks especially when stalwarts like BCLI or ATXH announce their phase II results. For that matter even ACT's itld release could be a good catalyst to activate the pumpers of such stocks. They tend to take advantage of gullible investors wanting to jump into the latest tech bandwagon.
|
|
|
Post by zangtum! on Jul 24, 2014 23:15:25 GMT
How do you assume this is life threatening? Because of what dayanand33 said above. Be careful here.
|
|
|
Post by JHam on Jul 25, 2014 2:10:20 GMT
How do you assume this is life threatening? wayandan, Because BHRT said it themselves in their 10-K last year: www.sec.gov/Archives/edgar/data/1388319/000114544313000874/d30274.htm(page 30) Our product candidates may never be commercialized due to unacceptable side effects and increased mortality that may be associated with such product candidates.
Possible side effects of our product candidates may be serious and life-threatening. A number of participants in our clinical trials of MyoCell have experienced serious adverse events potentially attributable to MyoCell, including six patient deaths and 18 patients experiencing irregular heartbeats.[/i][/b] A serious adverse event is generally an event that results in significant medical consequences, such as hospitalization, disability or death, and must be reported to the FDA. The occurrence of any unacceptable serious adverse events during or after preclinical and clinical testing of our product candidates could temporarily delay or negate the possibility of regulatory approval of our product candidates and adversely affect our business. Both our trials and independent trials have reported the occurrence of irregular heartbeats in treated patients, a significant risk to patient safety. We and our competitors have also, at times, suspended trials studying the effects of myoblasts, at least temporarily, to assess the risk of irregular heartbeats, and it has been reported that one of our competitors studying the effect of myoblast implantation prematurely discontinued a study because of the high incidence of irregular heartbeats. While we believe irregular heartbeats may be manageable with the use of certain prophylactic measures including an ICD, and antiarrhythmic drug therapy, these risk management techniques may not prove to sufficiently reduce the risk of unacceptable side effects.
|
|
|
Post by JHam on Jul 25, 2014 4:29:21 GMT
Good luck dayan.
It is a stock that has wild swings due the nature of it's pump and dumps. I feel sorry for those who bought when it was up 50% today thinking it was going to the moon, only for it to come crumbling back down.
Sure it is possible to make money with this stock, but the risk involved is just way too high for me to make that mistake again. There are too many legitimate companies with real science out there, doing it the right way, to get involved with this one, for me at least.
Then there is the whole ethical issue of the CEO Mike Tomas, with the help of his friend Jason Gruner (as shown in court documents), actually trying to sue posters on Yahoo who were pointing out the realities and risks involved with this company. Maybe it's just me, but I also see a major conflict of interest knowing that Tomas writes a blog on a site run by Gruner. Not to mention Gruner sending emails to members of his site threatening violence if they posted anything negative about BHRT on his site.
The whole thing is really ridiculous honestly and just leaves a bad taste in my mouth.
|
|
|
Post by tradeup on Jul 25, 2014 19:27:50 GMT
Feed better watch out ...
SEC Investor Alert: Social Media and Investing -- Stock Rumors
July 25, 2014
The U.S. Securities and Exchange Commission’s (SEC) Office of Investor Education and Advocacy (“OIEA”) is issuing this Investor Alert to warn investors about fraudsters who may attempt to manipulate share prices by using social media to spread false or misleading information about stocks.
Social media and the Internet in general have become important tools for investors. Investors may use social media to research particular stocks, look up background information on a broker-dealer or investment adviser, find guidance on investing strategies, receive up-to-date news, and discuss the markets with others.
While social media can provide many benefits for investors, it also presents opportunities for fraudsters. Through social media, fraudsters can spread false or misleading information about a stock to large numbers of people with minimum effort and at a relatively low cost. They can also conceal their true identities by acting anonymously or even impersonating credible sources of market information.
One way fraudsters may exploit social media is to engage in a market manipulation, such as spreading false and misleading information about a company to affect the stock’s share price. Wrongdoers may perpetuate stock rumors on social media, as well as on online bulletin boards and in Internet chat rooms.
The false or misleading rumors may be positive or negative. For example, in a “pump-and-dump” scheme, promoters “pump” up the stock price by spreading positive rumors that incite a buying frenzy and they quickly “dump” their own shares before the hype ends. Typically, after the promoters profit from their sales, the stock price drops and the remaining investors lose money. In other instances, fraudsters start negative rumors urging investors to sell their shares so that the stock price plummets and the fraudsters take advantage of buying shares at the artificially low price.
SEC Enforcement Action Involving Social Media and Market Manipulation
The SEC has charged individuals for committing securities fraud through the use of social media.
In SEC v. McKeown and Ryan, the SEC obtained judgments against a Canadian couple who used their website (PennyStockChaser), Facebook, and Twitter to pump up the stock of microcap companies, and then profited by selling shares of those companies. The couple allegedly received millions of shares of these companies as compensation and sold the shares around the time that their website predicted the stock price would massively increase (a practice known as “scalping”). The SEC’s complaint alleged that the couple did not fully disclose the compensation they received for touting the stocks. The court ordered the couple and their companies to pay more than $3.7 million in disgorgement for profits gained as a result of the alleged conduct, and ordered the couple to pay $300,000 in civil penalties.
Investors should be aware that fraudsters may use social media to impersonate an established source of market information. For example, fraudsters may set up an account name, profile, or handle designed to mimic a particular company or securities research firm. They may go so far as to create a webpage that uses the company’s logo, links to the company’s actual website, or references the name of an actual person who works for the company.
When you receive investment information through social media, verify the identity of the underlying source. Look for slight variations or typos in the sender’s account name, profile, email address, screen name, or handle, or other signs that the sender may be an imposter. Determine whether information appearing to be from a particular company or securities research firm is authentic. When contacting a company or attempting to access its website, be sure to use contact information or the website address provided by the company itself, such as in the company’s SEC filings. Carefully type the website’s address into the address bar of your web browser.
Some social media operators have systems that may help you to determine whether or not a sender is genuine. For example, Twitter verifies accounts for authenticity by posting a blue verified badge (a solid blue circle containing a white checkmark) on Twitter profiles. While a verified account does not guarantee that the source is genuine, be more skeptical of information from accounts that are not verified.
Think twice about investing if you spot any of these red flags of investment fraud:
Limited history of posts. Fraudsters can set up new accounts specifically designed to carry out their scam while concealing their true identities. Be skeptical of information from social media accounts that lack a history of prior postings or sending messages.
Pressure to buy or sell RIGHT NOW. Take the time to research the stock before you invest. Be skeptical of messages urging you to buy a hot stock before you “miss out” or to sell shares of a stock you own before the price goes down after negative news is announced. Be especially wary if the promoter claims the recommendation is based on “inside” or confidential information.
Unsolicited investment information or offers. Fraudsters may look for victims on social media sites, chat rooms, and bulletin boards. Exercise extreme caution regarding information provided in new posts on your wall, tweets, direct messages, e-mails, or other communications that solicit an investment or provide information about a particular stock if you do not personally know the sender (even if the sender appears connected to someone you know).
Unlicensed sellers. Federal and state securities laws require investment professionals and their firms who offer and sell investments to be licensed or registered. Many fraudulent investment schemes involve unlicensed individuals or unregistered firms. Check license and registration status by searching the SEC’s Investment Adviser Public Disclosure (IAPD) website or the Financial Industry Regulatory Authority (FINRA)’s BrokerCheck website.
Investors who learn of investing opportunities from social media should always be on the lookout for fraud. If you are aware of possible securities fraud, including potential market manipulation, submit a tip or complaint to the SEC.
To report a problem or to ask a question, submit a complaint or question to the SEC or call the SEC’s toll-free investor assistance line at (800) 732-0330 (dial 1-202-551-6551 if calling from outside of the United States).
|
|
|
Post by tradeup on Nov 15, 2014 14:38:04 GMT
Looks like BHRT is back to pre- "iCell pump" price. This one is going sub-penny.
|
|
|
Post by JHam on Nov 16, 2014 22:13:42 GMT
Looks like BHRT is back to pre- "iCell pump" price. This one is going sub-penny. It's ironic how the owner of that site, who admits he has a personal relationship with CEO Mike Tomas (heck there is even a court affidavit where he gave a testimony for him), openly orchcestrates a pump to manipulate the the share price on iCell, and icellman comes over here and accuses some of us of having an agenda, lol.
|
|
asusdelux
Junior Member
UP listed.. now what?
Posts: 66
|
Post by asusdelux on Nov 16, 2014 22:52:43 GMT
its pretty obvious JG is a shill and a scam artist at that. Did anything ever come of him misleading Icellers into believing membership fees would in part be donated to charity? Does anyone know where you can send a letter to report that type of abuse?
|
|